BrECADD Regimen Improves PFS vs eBEACOPP Regimen in Advanced Classical Hodgkin Lymphoma
Four-year progression-free survival outcomes revealed the BrECADD regimen was superior to the eBEACOPP regimen, and BrECADD had a promising benefit-risk profile.
Source: onclive.com